<DOC>
	<DOCNO>NCT01013272</DOCNO>
	<brief_summary>Patients chronic hepatitis B treat entecavir 6 month ( previous antiviral treatment ) invite participate study . They eligible liver test normal viral load undetectable . Patients switch lamivudine treatment ass whether lamivudine maintain adequate suppression hepatitis B virus successful treatment entecavir . Patients monitor closely switch treatment 1 month every 3 monthly . If evidence increase viral load patient give option change back entecavir .</brief_summary>
	<brief_title>Lamivudine Therapy Patients With Prior Entecavir Treatment Undetectable Viral Load</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients chronic hepatitis B treat entecavir 6 month Normal ALT Undetectable HBV DNA Roche Taqman PCR Assay No previous therapy nucleoside/nucleotide analogue Presence liver diseases include hepatitis C coinfection , autoimmune hepatitis , primary biliary cirrhosis , primary sclerosing cholangitis , alcoholic liver disease , Wilson 's disease History hepatocellular carcinoma History decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>entecavir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>sequential therapy</keyword>
</DOC>